UNSPSC 51181610: Montirelin

This classification denotes a thyrotropin-releasing hormone analogue with the molecular formula C17H24N6O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 30MUJ6YYUY, chemically known as (-)-n-(((3r,6s)-6-methyl-5-oxo-3-thiomorpholinyl)carbonyl)-l-histidyl-l-prolinamide but generally known as montirelin, which bears US NIH Compound Identifier 65815. European Medicines Agency schedules Montirelin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09056MIG.

UNSPSC 51181610 Montirelin is a Commodity code representing pharmaceutical active ingredients and finished pharmaceutical products supplied to state and local healthcare systems, educational institutions, and correctional facilities. State and local governments procure these products primarily through cooperative purchasing alliances and multistate contracts that aggregate demand across multiple jurisdictions and authorized wholesaler networks. The scope of work encompasses the supply of generic multi-source pharmaceuticals, over-the-counter products, and prescription medications distributed via established pharmaceutical wholesalers with chargeback systems and electronic data interchange capabilities. Issuing bodies include state departments of administration and health, multistate cooperative purchasing organizations (such as MMCAP), county health systems, and public hospital networks. Vendors must maintain cGMP certification, Drug Supply Chain Security Act compliance, relationships with multiple authorized wholesalers, and comprehensive insurance coverage including commercial general liability of $5,000,000 per occurrence and professional liability of $2,000,000.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted a Request for Proposal on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products serving participating state and local government facilities across Minnesota and Oregon. Proposals were due March 26, 2026, with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing for the contract term, and 5 percent each on administrative compliance, EDI capability, and agreement to a 3 percent administrative fee. Awarded vendors will begin supplying through authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) effective July 1, 2026, on two-year terms with optional extensions through June 30, 2028. Vendors must submit detailed product information including National Drug Codes, SKUs, UPCs, and packaging configurations, with pricing submitted in flat price, net price, or WAC-minus formats through the ePro procurement system.